Indaptus TherapeuticsINDP -10.00%26 Buyback Yield % is -0.64 as of Jun. 30, 2026. GuruFocus rates INDP with a GF Score™ of 26/100. The stock has 1 warning sign investors should review. Among 742 Biotechnology companies, Indaptus Therapeutics ranks better than 74.12% on this metric.
Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.
Indaptus Therapeutics Buyback Yield % Related Terms
Indaptus Therapeutics Buyback Yield % Historical Data
* Premium members only.
The historical data trend for Indaptus Therapeutics's Buyback Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
INDP vs EDIT, ARTV, SGMT: Buyback Yield % Comparison
For the Biotechnology subindustry, Indaptus Therapeutics's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Indaptus Therapeutics Buyback Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Indaptus Therapeutics's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where Indaptus Therapeutics's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Indaptus Therapeutics (INDP) has a Buyback Yield % of -0.64 as of Jun. 30, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Indaptus Therapeutics and its competitors. According to the industry distribution chart, Indaptus Therapeutics ranks #192 out of 742 companies in the Biotechnology industry, placing it in the top 25.9%.
Is Indaptus Therapeutics' Buyback Yield % too high?
Indaptus Therapeutics' current Buyback Yield % is -0.64. Based on the distribution chart, Indaptus Therapeutics ranks #192 out of 742 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Indaptus Therapeutics has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Indaptus Therapeutics' Buyback Yield % compare to EDIT and ARTV?
According to the Biotechnology industry distribution chart, Indaptus Therapeutics ranks #192 out of 742 companies for Buyback Yield %. This puts Indaptus Therapeutics in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Biotechnology company?
A good Buyback Yield % depends on the Biotechnology industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Indaptus Therapeutics and its competitors. Indaptus Therapeutics's current Buyback Yield % is -0.64. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Indaptus Therapeutics stock overvalued right now?
Indaptus Therapeutics (INDP) has a current Buyback Yield % of -0.64. The current Buyback Yield % is -0.64. Indaptus Therapeutics' overall GF Score™ is 26/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Indaptus Therapeutics (INDP), the current Buyback Yield % is -0.64 as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Indaptus Therapeutics Inc is a clinical biotechnology company that has developed a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. Its approach is based on the hypothesis that efficient activation of both innate and adaptive immune cells and associated anti-tumor and anti-viral immune responses will require a multi-targeted package of immune system activating signals that can be administered safely intravenously. Its patented technology is composed of single strains of attenuated and killed, non-pathogenic, Gram-negative bacteria, designed to have reduced i.v. toxicity, but largely uncompromised ability to prime or activate many of the cellular components of innate and adaptive immunity. Its candidate, Decoy20 is for patients with solid tumors.
26GF Score
Get the complete analysis for INDP
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
INDP has been successfully added to your 
